{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:04:17Z","timestamp":1793678657137,"version":"4.5.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.kint.2023.02.029","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T18:34:59Z","timestamp":1679337299000},"page":"1144-1155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis"],"prefix":"10.1016","volume":"103","author":[{"given":"Nicolas","family":"Benichou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Terrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel B.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hiemstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Mouthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg","family":"Bajema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Berden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Thervet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Guillevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Karras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2023.02.029_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2023.02.029_bib2","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2023.02.029_bib3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.02.029_bib4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.02.029_bib5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2023.02.029_bib6","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2215\/CJN.01020113","article-title":"Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis","volume":"8","author":"de Joode","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.02.029_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2013-203927","article-title":"Damage in the ANCA-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials","volume":"74","author":"Robson","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2023.02.029_bib8","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/art.39614","article-title":"Trends in long-term outcomes among patients with antineutrophil cytoplasmic antibody-associated vasculitis with renal disease","volume":"68","author":"Rhee","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2023.02.029_bib9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/rheumatology\/key260","article-title":"Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome","volume":"58","author":"Wester Trejo","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.kint.2023.02.029_bib10","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1046\/j.1523-1755.2003.00843.x","article-title":"Rapidly progressive crescentic glomerulonephritis","volume":"63","author":"Jennette","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.02.029_bib11","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1046\/j.1523-1755.2003.00868.x","article-title":"Proteinuria and the risk of developing end-stage renal disease","volume":"63","author":"Iseki","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.02.029_bib12","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2023.02.029_bib13","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/jama.2010.39","article-title":"Relation between kidney function, proteinuria, and adverse outcomes","volume":"303","author":"Hemmelgarn","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2023.02.029_bib14","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1046\/j.1523-1755.1998.00874.x","article-title":"\u201cGruppo Italiano di Studi Epidemiologici in Nefrologia\u201d (GISEN). Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies","volume":"53","author":"Ruggenenti","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.02.029_bib15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.7326\/M20-0529","article-title":"Conversion of urine protein-creatinine ratio or urine dipstick protein to urine albumin-creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant-based meta-analysis","volume":"173","author":"Sumida","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2023.02.029_bib16","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.02.029_bib17","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1136\/annrheumdis-2020-216965","article-title":"Lack of EULAR\/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis","volume":"79","author":"Moroni","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2023.02.029_bib18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2215\/CJN.04160417","article-title":"The utility of urinalysis in determining the risk of renal relapse in ANCA-associated vasculitis","volume":"13","author":"Rhee","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.02.029_bib19","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2023.02.029_bib20","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.02.029_bib21","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2023.02.029_bib22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2023.02.029_bib23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of systemic vasculitides: proposal of an international consensus conference","volume":"37","author":"Jennette","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2023.02.029_bib24","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2010050477","article-title":"Histopathologic classification of ANCA-associated glomerulonephritis","volume":"21","author":"Berden","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.02.029_bib25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.kint.2023.02.029_bib26","first-page":"1","article-title":"mice: Multivariate Imputation by Chained Equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J\u00a0Stat Softw"},{"key":"10.1016\/j.kint.2023.02.029_bib27","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.kint.2018.07.020","article-title":"Development and validation of a renal risk score in ANCA-associated glomerulonephritis","volume":"94","author":"Brix","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.02.029_bib28","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1046\/j.1523-1755.1999.00758.x","article-title":"Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis","volume":"56","author":"Bajema","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.02.029_bib29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/ndt\/gfh563","article-title":"Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis","volume":"20","author":"Neumann","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.02.029_bib30","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1080\/0886022X.2018.1487865","article-title":"Clinical and pathologic characteristics of pauci-immune anti-myeloperoxidase antibody associated glomerulonephritis with nephrotic range proteinuria","volume":"40","author":"Xu","year":"2018","journal-title":"Ren Fail"},{"key":"10.1016\/j.kint.2023.02.029_bib31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.kint.2018.11.008","article-title":"Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.02.029_bib32","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1681\/ASN.V9101915","article-title":"Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis","volume":"9","author":"Franssen","year":"1998","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.02.029_bib33","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/ndt\/17.4.587","article-title":"Long-term renal injury in ANCA-associated vasculitis: an analysis of 31 patients with follow-up biopsies","volume":"17","author":"Hauer","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.02.029_bib34","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/ndt\/gfu042","article-title":"Repeat protocol renal biopsy in ANCA-associated renal vasculitis","volume":"29","author":"Hruskova","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.02.029_bib35","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.02.029_bib36","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.kint.2018.05.021","article-title":"A\u00a0prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy","volume":"94","author":"De Rosa","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.02.029_bib37","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.kint.2019.07.018","article-title":"Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis","volume":"97","author":"Malvar","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.02.029_bib38","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1159\/000500352","article-title":"Prognostic value of microscopic hematuria after induction of remission in antineutrophil cytoplasmic antibodies-associated vasculitis","volume":"49","author":"Vandenbussche","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2023.02.029_bib39","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12882-017-0763-7","article-title":"Persistent hematuria in patients with antineutrophil cytoplasmic antibody-associated vasculitis during clinical remission: chronic glomerular lesion or low-grade active renal vasculitis?","volume":"18","author":"Lv","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2023.02.029_bib40","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3899\/jrheum.111608","article-title":"Persistent or new onset microscopic hematuria in patients with small vessel vasculitis in remission: findings on renal biopsy","volume":"39","author":"Geetha","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.kint.2023.02.029_bib41","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1093\/rheumatology\/keab695","article-title":"Utility of interval kidney biopsy in ANCA-associated vasculitis","volume":"61","author":"Chapman","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.kint.2023.02.029_bib42","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-143-9-200511010-00005","article-title":"Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis","volume":"143","author":"Hogan","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2023.02.029_bib43","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1002\/art.23800","article-title":"Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts","volume":"58","author":"Pagnoux","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2023.02.029_bib44","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.33361","article-title":"Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Walsh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2023.02.029_bib45","doi-asserted-by":"crossref","first-page":"rkab018","DOI":"10.1093\/rap\/rkab018","article-title":"Predicting relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic review and meta-analysis","volume":"5","author":"King","year":"2021","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.kint.2023.02.029_bib46","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2023.02.029_bib47","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/art.40724","article-title":"Establishing surrogate kidney end points for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes","volume":"71","author":"Mackay","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2023.02.029_bib48","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.ekir.2019.08.007","article-title":"Implementing the kidney health initiative surrogate efficacy endpoint in patients with IgA nephropathy (the PROTECT Trial)","volume":"4","author":"Barratt","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2023.02.029_bib49","first-page":"119","article-title":"Surrogate end points in clinical trials: the case of anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"20","author":"Walsh","year":"2007","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.kint.2023.02.029_bib50","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ki.2009.218","article-title":"The clinical course of ANCA\u00a0small-vessel vasculitis on chronic dialysis","volume":"76","author":"Lionaki","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.02.029_bib51","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","article-title":"Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial","volume":"14","author":"Praga","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.02.029_bib52","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1056\/NEJMra1106556","article-title":"Focal segmental glomerulosclerosis","volume":"365","author":"D\u2019Agati","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.02.029_bib53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A\u00a0pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.02.029_bib54","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/ndt\/gfy300","article-title":"Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"35","author":"Moran","year":"2020","journal-title":"Nephrol Dial Transplant"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823001680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823001680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:04:25Z","timestamp":1758762265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253823001680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0085253823001680"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2023.02.029","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2023.02.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}